Egaxf1uqtgcippjq1ssq imanova

Imanova Ltd.

London, London, GB

Drug development is a time consuming, complex, risky and expensive venture. There is an increasing requirement to find ways to accelerate and reduce the cost of decision making so that only the best candidate molecules progress to the later stages of drug development.

Imanova is a translational research company that specialises in applying positron emission tomography (PET) and magnetic resonance imaging (MRI) scanning techniques to improve productivity in early drug development and to help improve disease understanding.

Established in 2011 Imanova was formed in an innovative alliance between the UK's Medical Research Council, Imperial College London, King's College London and University College London to act as a conduit between academia and industry.

Since inception, Imanova has completed over 50 clinical studies and is in a unique position to facilitate productive, mutually beneficial relationships... Show more »

Drug development is a time consuming, complex, risky and expensive venture. There is an increasing requirement to find ways to accelerate and reduce the cost of decision making so that only the best candidate molecules progress to the later stages of drug development.

Imanova is a translational research company that specialises in applying positron emission tomography (PET) and magnetic resonance imaging (MRI) scanning techniques to improve productivity in early drug development and to help improve disease understanding.

Established in 2011 Imanova was formed in an innovative alliance between the UK's Medical Research Council, Imperial College London, King's College London and University College London to act as a conduit between academia and industry.

Since inception, Imanova has completed over 50 clinical studies and is in a unique position to facilitate productive, mutually beneficial relationships between academia and industry.

Recent Publications

  • Quantitative analysis of dynamic 18F-FDG PET/CT for measurement of lung inflammation. Coello C, Fisk M, Mohan D, Wilson FJ, Brown AP, Polkey MI, Wilkinson I, Tal-Singer R, Murphy PS, Cheriyan J, Gunn RN. EJNMMI Res. 2017 Dec;7(1):47. doi: 10.1186/s13550-017-0291-2. Epub 2017 May 25.
  • Pro-inflammatory activation of primary microglia and macrophages increases 18 kDa translocator protein expression in rodents but not humans. Owen DR, Narayan N, Wells L, Healy L, Smyth E, Rabiner EA, Galloway D, Williams JB, Lehr J, Mandhair H, Peferoen LA, Taylor PC, Amor S, Antel JP, Matthews PM, Moore CS. J Cereb Blood Flow Metab. 2017 Jan 1:271678X17710182. doi: 10.1177/0271678X17710182. [Epub ahead of print]
  • Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson's disease. Martin-Bastida A, Ward RJ, Newbould R, Piccini P, Sharp D, Kabba C, Patel MC, Spino M, Connelly J, Tricta F, Crichton RR, Dexter DT. Sci Rep. 2017 May 3;7(1):1398. doi: 10.1038/s41598-017-01402-2.
  • 11 C-DPA-713 has much greater specific binding to translocator protein 18 kDa (TSPO) in human brain than 11 C-( R )-PK11195. Kobayashi M, Jiang T, Telu S, Zoghbi SS, Gunn RN, Rabiner EA, Owen DR, Guo Q, Pike VW, Innis RB, Fujita M. J Cereb Blood Flow Metab. 2017 Jan 1:271678X17699223. doi: 10.1177/0271678X17699223. [Epub ahead of print]
  • [11C]PBR28 or [18F]PBR111 detect white matter inflammatory heterogeneity in multiple sclerosis. Datta G, Colasanti A, Kalk N, Owen DR, Scott G, Rabiner EI, Gunn R, Lingford-Hughes A, Malik O, Ciccarelli O, Nicholas R, Nie L, Battaglini M, De Stefano N, Matthews P. J Nucl Med. 2017 Mar 16. pii: jnumed.116.187161. doi: 10.2967/jnumed.116.187161. [Epub ahead of print]
  • Naltrexone ameliorates functional network abnormalities in alcohol-dependent individuals. Morris LS, Baek K, Tait R, Elliott R, Ersche KD, Flechais R, McGonigle J, Murphy A, Nestor LJ, Orban C, Passetti F, Paterson LM, Rabiner I, Reed L, Smith D, Suckling J, Taylor EM, Bullmore ET, Lingford-Hughes AR, Deakin B, Nutt DJ, Sahakian BJ, Robbins TW, Voon V; ICCAM Consortium. Addict Biol. 2017 Feb 28. doi: 10.1111/adb.12503. [Epub ahead of print]
  • Nalmefene Reduces Reward Anticipation in Alcohol Dependence: An Experimental Functional Magnetic Resonance Imaging Study. Quelch DR, Mick I, McGonigle J, Ramos AC, Flechais RS, Bolstridge M, Rabiner E, Wall MB, Newbould RD, Steiniger-Brach B, van den Berg F, Boyce M, Østergaard Nilausen D, Breuning Sluth L, Meulien D, von der Goltz C, Nutt D, Lingford-Hughes A. Biol Psychiatry. 2017 Jan 10. pii: S0006-3223(17)30008-2. doi: 10.1016/j.biopsych.2016.12.029. [Epub ahead of print]
  • Neural substrates of cue reactivity and craving in gambling disorder. E H Limbrick-Oldfield, I Mick, R E Cocks, J McGonigle, S P Sharman, A P Goldstone, P R A Stokes, A Waldman, D Erritzoe, H Bowden-Jones, D Nutt, A Lingford-Hughes and L Clark Citation: Translational Psychiatry (2017) 7, e992; doi:10.1038/tp.2016.256
    Published online 3 January 2017
  • Decreased hippocampal translocator protein (18 kDa) expression in alcohol dependence: a [11C]PBR28 PET study. Kalk NJ, Guo Q, Owen D, Cherian R, Erritzoe D, Gilmour A, Ribeiro AS, McGonigle J, Waldman A, Matthews P, Cavanagh J, McInnes I, Dar K, Gunn R, Rabiner EA, Lingford-Hughes AR. Transl Psychiatry. 2017 Jan 10;7(1):e996. doi: 10.1038/tp.2016.264.
  • Imaging in Central Nervous System Drug Discovery. Gunn RN, Rabiner EA. Semin Nucl Med. 2017 Jan;47(1):89-98. doi: 10.1053/j.semnuclmed.2016.09.001. Review. PMID: 27987561
  • T2 relaxation mapping MRI of healthy and inflamed gingival tissue. Newbould RD, Bishop CA, Janiczek RL, Parkinson C, Hughes FJ. Dentomaxillofac Radiol. 2017 Feb;46(2):20160295. doi: 10.1259/dmfr.20160295.
    PMID: 27936919
  • Quantification of Lung PET Images: Challenges and Opportunities. Delphine L Chen, Joseph Cheriyan, Edwin Chilvers, Gourab Choudoury, Christopher Coello, Martin Connell, Marie Fisk, Ashley M Groves, Roger N Gunn, Beverley F Holman, Brian F Hutton, Sarah Lee, William MacNee, Divya Mohan, David Parr, Deepak Subramanian, Ruth Tal-Singer, Kris Thielemans, Edwin JR van Beek, Laurence Vass, Jeremy W Wellen, Ian Wilkinson and Frederick J Wilson. J Nucl Med January 12, 2017 jnumed.116.184796
« Show less

Imanova Ltd. has not listed any services.

Clinical Positron Emission Tomography
Price on request
Request a quote for more information about this service.
MRI Data Analysis
Price on request
Request a quote for more information about this service.
Clinical Imaging Services
Price on request

Clinical imaging in humans can help companies to improve productivity and de-risk their drug development process. Imanova provide world class translational medicine capabilities by bringing together world class scanning equipment, radio-ligand development and imaging research methodology. Depending on the requirement of the... Show more »

Clinical imaging in humans can help companies to improve productivity and de-risk their drug development process. Imanova provide world class translational medicine capabilities by bringing together world class scanning equipment, radio-ligand development and imaging research methodology. Depending on the requirement of the Imanova provides:

  • Positron Emission Tomography (PET) Imaging services - Molecular imaging with PET uses compounds radiolabelled with tracer amounts of radioactivity to image human biological function in vivo. PET imaging in early clinical development, often in parallel with the first in human studies, helps determine the drug distribution, target interaction and downstream pharmacology. Such information can be used to provide dosing information for proof-of-concept studies, which has been demonstrated to reduce both cost and time in early stage development.
  • Magnetic Resonance Imaging (MRI) - A non-invasive medical imaging technique used in radiology to investigate the anatomy and physiology of the body in both health and disease. MRI scanners use magnetic fields and radio waves to form images of the body. Imanova provides a range of MRI solutions including:
    • Functional MRI (fMRI) – to understand how different parts of the brain respond to external stimuli
    • Structural MRI – to provide detailed images of soft tissues in the body to monitor disease progression in areas such as inflammatory arthritis, respiratory disease and neurodegeneration
    • Magnetic Resonance Spectroscopy (MRS) – for measuring metabolism and target metabolites in tissues such as muscle and brain
  • Working in collaboration with academic, research and commercial organisations, Imanova aims to provide access to:
    • Internationally renowned scientists and clinical research staff, operating across all key aspects of Imaging Sciences
    • Meet the requirements of commercial partners, and operate within a high level GMP/GCP environment
    • Extensive experience in designing, conducting and analysing imaging studies to deliver information that will allow critical decision making.
« Show less
Small Animal PET Scan
Small Animal Positron Emission Tomography Scan
Price on request

At Imanova, the clinical imaging portfolio is supported by an extensive range of preclinical services and other supporting technologies.

PET can help quantify and determine the biodistribution or target engagement of the candidate drug and understand the mechanisms of disease in vivo. Preclinical PET enables the Imanova... Show more »

At Imanova, the clinical imaging portfolio is supported by an extensive range of preclinical services and other supporting technologies.

PET can help quantify and determine the biodistribution or target engagement of the candidate drug and understand the mechanisms of disease in vivo. Preclinical PET enables the Imanova scientists to:

  • Evaluate and characterise novel radiotracers and drugs prior to their administration in humans to:
    • Allow candidate selection through occupancy (dose-ranging) studies
    • Demonstrate early proof-of-principle and in vivo target engagement
    • Characterise novel radiotracers through the application of precision pharmacology
  • Allows development and assessment of imaging protocols and techniques prior to (and during) clinical implementation.
  • Enables the relevant experimental questions to be addressed that cannot be answered in human subjects during clinical studies.

The rodent imaging suite at Imanova houses a purpose built Siemens Inveon PET-CT scanner and supporting technologies. Imanova has implemented a broad range of disease models, and through its academic links has access to many more at short notice. All procedures are performed in accordance with the ASPA 1986 and EU directive 2010/63/EU.

We have extensive experience with supportive in vitro techniques, including autoradiography, radioligand binding and microscopy staining techniques, to correlate biological changes with quantitative imaging outcomes.

« Show less
Biomarkers
Price on request

Biomarker is a “biological indicator” used to measure onset and progression of a disease or as a marker of drug safety such as body temperature, blood pressure and heart rate. Imaging biomarkers (i-Biomarker) are used at Imanova to:

  • Determine if the candidate drug reaches and engages the target
  • Quantify the relationship... Show more »

Biomarker is a “biological indicator” used to measure onset and progression of a disease or as a marker of drug safety such as body temperature, blood pressure and heart rate. Imaging biomarkers (i-Biomarker) are used at Imanova to:

  • Determine if the candidate drug reaches and engages the target
  • Quantify the relationship between administered dose and target engagement
  • Investigate the relationship between target and disease
  • Demonstrate dose-dependent functional effects of candidate drug
  • Define the ‘therapeutic window’ to optimise dose selection and minimise side effects

Imaging biomarkers have the advantage of being non-invasive and can be used for early detection of diseases, patient stratification, and provide an objective assessment for the response to treatment.

The main limiting factor for using molecular imaging studies for early stage drug development decision-making is the lack of available biomarkers. Imanova is an advocate of using imaging as an integral part of clinical research to help understand the basis of disease and in the support of the drug development process and has a dedicated i-Biomarker discovery and development service.

Imanova has developed and implemented 21 imaging biomarkers to Good Manufacturing Practice (GMP) standard since its inception. We have the capability and experience to help identify, evaluate, develop and implement biomarker candidates for use in both preclinical models and clinical (in humans) studies.

In addition to neurosciences, Imanova offers i-Biomarker development for other key therapeutic areas including oncology, inflammation, cardiology and respiratory diseases.

« Show less
Radiochemistry
Price on request
Request a quote for more information about this service.
Clinical MRI
Clinical Magnetic Resonance Imaging
Price on request
Request a quote for more information about this service.
Animal Model in vivo Analyses
Price on request
Request a quote for more information about this service.
Chemistry and Materials
Price on request
Request a quote for more information about this service.
Pharmacology & Toxicology
Price on request
Request a quote for more information about this service.
Clinical Research
Price on request
Request a quote for more information about this service.
Animal Imaging
Price on request
Request a quote for more information about this service.
Bioanalysis
Price on request
Request a quote for more information about this service.
Animal Models and Studies
Price on request
Request a quote for more information about this service.
Ask A Question Find what you're looking for? If not, you can ask this lab a question:

Imanova Ltd. has not received any ratings.

Be the first to endorse Imanova Ltd.

Endorse this lab